Sign up
Pharma Capital

Growth 'guaranteed' for a well funded Volition Rx

Cameron Reynolds, CEO of Volition Rx, the NYSE-listed company, brings Proactive Investors London an end of quarter catch up with newsflows in three key areas. First there's more news on their new routine blood test to screen for colorectal and prostate cancers which has reduced the need for more invasive colonoscopies and biopsies. Secondly, there's an update on the potential for further revenue streams for Volition once discovery grade assets convert to product grade opportunities. And lastly, how Volition continues to push into veterinary medicine while both well funded and keeping costs down.

 

View full VNRX profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.